Yahoo España Búsqueda web

  1. 161.000 resultados de búsqueda aproximadamente

  1. 2019 Oct;121 (9):725-737. doi: 10.1038/s41416-019-0573-8. Osimertinib is an irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer (NSCLC) with EGFR oncogene ...

  2. 1 de jun. de 1993 · Paola Perego. Nature Reviews Cancer (2021) Acquired resistance to cisplatin (DDP) is a major clinical problem in the treatment of ovarian, testicular, and head and neck carcinomas; decreased ...

  3. 15 de sept. de 2022 · Paola Perego, chi è: marito, figli, nonna e vita privata. Non si sa così tanto sulla vita privata di Paola Perego. Suo marito, per tanti anni, è stato il calciatore Andrea Carnevale, da lei conosciuto a metà degli anni ottanta. Assieme hanno avuto 2 figli. Paola però chiese il divorzio nel 1997.

  4. 20 de jul. de 2023 · Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. Critical reviews in oncology/hematology. 2015-05 | Journal article. DOI: 10.1016/j.critrevonc.2014.11.005.

  5. Alessandra Bracaglia is on Facebook. Join Facebook to connect with Alessandra Bracaglia and others you may know. Facebook gives people the power to share and makes the world more open and connected.

  6. Affiliations 1 Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.; 2 Molecular Pharmacology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Electronic address: paola.perego@istitutotumori.mi.it.

  7. Giovanni L Beretta 1 , Sabina C Righetti, Luciano Lombardi, Franco Zunino, Paola Perego. Affiliation 1 Department of Experimental Oncology, Istituto Nazionale Tumori, Milan, Italy. PMID: 12396244 DOI: 10.1080/01913120290104610 Abstract Taking advantage of the ...